Abstract:Overnutrition, usually with obesity and genetic predisposition, lead to insulin resistance, which is an invariable accompaniment of nonalcoholic fatty liver disease (NAFLD). The associated metabolic abnormalities, pre- or established diabetes, hypertension and atherogenic dyslipidemia (clustered as metabolic syndrome) tend to be worse for nonalcoholic steatohepatitis (NASH), revealing it as part of a continuum of metabolic pathogenesis. The origins of hepatocellular injury and lobular inflammation which distinguish NASH from simple steatosis have intrigued investigators, but it is now widely accepted that NASH results from liver lipotoxicity. The key issue is not the quantity of liver fat but the type(s) of lipid molecules that accumulate, and how they are "packaged" to avoid subcellular injury. Possible lipotoxic mediators include free (unesterified) cholesterol, saturated free fatty acids, diacylglycerols, lysophosphatidyl-choline, sphingolipids and ceramide. Lipid droplets are intracellular storage organelles for non-structural lipid whose regulation is influenced by genetic polymorphisms, such as PNPLA3. Cells unable to sequester chemically reactive lipid molecules undergo mitochondrial injury, endoplasmic reticulum (ER) stress and autophagy, all processes of interest for NASH pathogenesis. Lipotoxicity kills hepatocytes by apoptosis, a highly regulated, non-inflammatory form of cell death, but also by necrosis, necroptosis and pyroptosis; the latter involve mitochondrial injury, oxidative stress, activation of c-Jun N-terminal kinase (JNK) and release of danger-associated molecular patterns (DAMPs). DAMPs stimulate innate immunity by binding pattern recognition receptors, such as Toll-like receptor 4 (TLR4) and the NOD-like receptor protein 3 (NLRP3) inflammasome, which release a cascade of pro-inflammatory chemokines and cytokines. Thus, lipotoxic hepatocellular injury attracts inflammatory cells, particularly activated macrophages which surround ballooned hepatocytes as crown-like structures. In both experimental and human NASH, livers contain cholesterol crystals which are a second signal for NLRP3 activation; this causes interleukin (IL)-1β and IL18 secretion to attract and activate macrophages and neutrophils. Injured hepatocytes also liberate plasma membrane-derived extracellular vesicles; these have been shown to circulate in NASH and to be pro-inflammatory. The way metabolic dysfunction leads to lipotoxicity, innate immune responses and the resultant pattern of cellular inflammation in the liver are likely also relevant to hepatic fibrogenesis and hepatocarcinogenesis. Pinpointing the key molecules involved pharmacologically should eventually lead to effective pharmacotherapy against NASH.

Lipocalin 2 induces neuroinflammation and blood-brain barrier dysfunction through liver-brain axis in murine model of nonalcoholic steatohepatitis

Lipocalin-2 as a mediator of neuroimmune communication

Lipocalin-2 in Diabetic Complications of the Nervous System: Physiology, Pathology, and Beyond

Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy

Lipocalin 2 as a Putative Modulator of Local Inflammatory Processes in the Spinal Cord and Component of Organ Cross talk After Spinal Cord Injury

Serum Lipocalin-2 is a Potential Biomarker for the Clinical Diagnosis of Nonalcoholic Steatohepatitis

Leukocyte Cell-Derived Chemotaxin 2 Promotes the Development of Nonalcoholic Fatty Liver Disease Through STAT-1 Pathway in Mice.

Hepatic Lipocalin 2 Promotes Liver Fibrosis and Portal Hypertension

Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease

Lipocalin-2 drives neuropsychiatric and cutaneous disease in MRL/lpr mice

The Detrimental Role Played by Lipocalin-2 in Alcoholic Fatty Liver in Mice.

The interaction of lipocalin-2 and astrocytes in neuroinflammation: mechanisms and therapeutic application

Altered mitochondrial and peroxisomal integrity in lipocalin-2-deficient mice with hepatic steatosis

Effects of lipocalin-2 on brain endothelial adhesion and permeability

Lipocalin-2 (LCN2) regulates PLIN5 expression and intracellular lipid droplet formation in the liver

Butyrate limits inflammatory macrophage niche in NASH

Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease

Lipocalin 2 is a regulator of macrophage polarization and NF-κB/STAT3 pathway activation

Lipocalin-2 Alleviates LPS-Induced Inflammation Through Alteration of Macrophage Properties

Lipocalin 10 is essential for protection against inflammation-triggered vascular leakage by activating LRP2-Ssh1 signaling pathway

Liver Lipocalin 2 Expression in Severely Obese Women With Non Alcoholic Fatty Liver Disease